202 related articles for article (PubMed ID: 19493068)
1. Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules.
Lybecker KM; Fowler E
J Law Med Ethics; 2009; 37(2):222-39. PubMed ID: 19493068
[TBL] [Abstract][Full Text] [Related]
2. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
Bird RC
J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
[TBL] [Abstract][Full Text] [Related]
3. Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options.
Reichman JH
J Law Med Ethics; 2009; 37(2):247-63. PubMed ID: 19493070
[TBL] [Abstract][Full Text] [Related]
4. An economic justification for open access to essential medicine patents in developing countries.
Flynn S; Hollis A; Palmedo M
J Law Med Ethics; 2009; 37(2):184-208. PubMed ID: 19493066
[TBL] [Abstract][Full Text] [Related]
5. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
Rosenberg ST
Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
[TBL] [Abstract][Full Text] [Related]
6. Is India ready to lead the battle for fair access to medicines?
Lancet Oncology
Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313
[No Abstract] [Full Text] [Related]
7. Amendments to the Canadian Patent Act to address drug access: is help on the way?
Penner MD; Narayanan P
Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
[No Abstract] [Full Text] [Related]
8. Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments.
Guennif S
Dev World Bioeth; 2017 Aug; 17(2):90-99. PubMed ID: 27699996
[TBL] [Abstract][Full Text] [Related]
9. Drug patent protection: how long is long enough?
Sibbald B
CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
[No Abstract] [Full Text] [Related]
10. A one-time-only combination: Emergency medicine exports and the TRIPS agreement under Canada's access to medicines regime.
Weber A; Mills L
Health Hum Rights; 2010 Jun; 12(1):109-22. PubMed ID: 20930258
[TBL] [Abstract][Full Text] [Related]
11. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
Jain D; Darrow JJ
Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
[TBL] [Abstract][Full Text] [Related]
12. Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
Ooms G; Forman L; Williams OD; Hill PS
BMC Int Health Hum Rights; 2014 Dec; 14():37. PubMed ID: 25518744
[TBL] [Abstract][Full Text] [Related]
13. Global patent police block cost-reduction efforts.
Kasper T
GMHC Treat Issues; 1999 Mar; 13(3):1-2. PubMed ID: 11366201
[TBL] [Abstract][Full Text] [Related]
14. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Berger JM
Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
[No Abstract] [Full Text] [Related]
15. Compulsory licensing of generic drugs remains mired in quagmires.
Chami G; Wasswa-Kintu S
CMAJ; 2011 Aug; 183(11):E705-6. PubMed ID: 21708968
[No Abstract] [Full Text] [Related]
16. Compulsory licensing and access to drugs.
Stavropoulou C; Valletti T
Eur J Health Econ; 2015 Jan; 16(1):83-94. PubMed ID: 24408475
[TBL] [Abstract][Full Text] [Related]
17. TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION.
Effingham AM
Seton Hall Law Rev; 2016; 46(3):883-909. PubMed ID: 27066613
[No Abstract] [Full Text] [Related]
18. The role of civil society in protecting public health over commercial interests: lessons from Thailand.
Ford N; Wilson D; Bunjumnong O; von Schoen Angerer T
Lancet; 2004 Feb; 363(9408):560-3. PubMed ID: 14975620
[No Abstract] [Full Text] [Related]
19. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
Halliburton M
Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
Lexchin J
Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
